13 August 2025 in Advanced Ophthalmology
Relevance. Fibrotic changes in filtration blebs after antiglaucoma surgeries limit the success of surgical glaucoma treatment. Therefore, there is a need for the development and evaluation of biocompatible and safe hydrogels. Purpose of the study. To study the local and general tolerability of a new polymer hydrogel when instilled into the eye of a rabbit under experimental conditions. Materials and methods. The study involved 12 (24 eyes) laboratory rabbits. The main group consisted of 4 (8 eyes) rabbits that were instilled with 3,5% Na-CMC hydrogel. The comparison group consisted of 4 (8 eyes) rabbits that were instilled with viscoelastic, and the control group consisted of 4 (8 eyes) rabbits that were instilled with 0.9% sodium chloride solution. The general condition of the animals, toxic-allergic reactions, and ophthalmological parameters (conjunctiva, cornea, intraocular pressure, and pupil diameter) were assessed. Results. The 3,5% Na-CMC hydrogel was well tolerated: the general condition of the animals remained within physiological norms, and no toxic or allergic manifestations were observed. Biomicroscopic examinations revealed no pathological changes in the anterior segment of the eye. Mild, temporary conjunctival hyperemia was observed but did not lead to persistent morphological changes. Intraocular pressure and pupil diameter remained within normal ranges. Conclusion. The 3,5% Na-CMC hydrogel demonstrates high biocompatibility and safety, making it a promising agent in ophthalmology, particularly for the preventionof fibrotic scarring after antiglaucoma surgeries.
20 August 2024 in Oftalmologicheskii Zhurnal
TATashkent Medical Academy
RNRepublican Specialized Scientific And Practical Medical Center For Narcology
Republican Specialized Scientific And Practical Medical Center For Narcology
+2
Introduction. Combined drug treatment of primary open-angle glaucoma (POAG) with several types of antihypertensive drops from different pharmacological groups is performed to enhance the hypotensive effect in cases when monotherapy does not always reduce intraocular pressure (IOP) to a tolerance level.Рurpose. Evaluation of the effectiveness and tolerability of a fixed combination antihypertensive drug, Glaubrinza, in the treatment of patients with POAG.Methods. Depending on the treatment, 2 groups of patients were formed. The main group included 30 patients (60 eyes), who instilled the drug Glaubrinza, 1 drop 2 times a day. The comparison group consisted of 30 patients (60 eyes), whom the drug Simbrinza was instilled according to the same scheme as the drug Glaubrinza.All patients underwent a general ophthalmological examination and special research methods, including: computer static perimetry, pachymetry, and optical coherence tomography (OCT). The local and general tolerability of the drug was assessed within 10 days using a standard scale.Results. The effectiveness of the treatment in the main group was assessed as high in 85% and moderately high in 15% and averaged 3.8±0.1 points. The effectiveness of treatment in the comparison group was assessed as moderately high in 20% and high in 80% of patients and averaged 3.8±0.03 points.Conclusions. Glaubrinza is a highly effective drug for treating POAG and is not inferior in all studied parameters to the reference drug and is also economically accessible to all segments of the population. Introduction. Combined drug treatment of primary open-angle glaucoma (POAG) with several types of antihypertensive drops from different pharmacological groups is performed to enhance the hypotensive effect in cases when monotherapy does not always reduce intraocular pressure (IOP) to a tolerance level.Рurpose. Evaluation of the effectiveness and tolerability of a fixed combination antihypertensive drug, Glaubrinza, in the treatment of patients with POAG.Methods. Depending on the treatment, 2 groups of patients were formed. The main group included 30 patients (60 eyes), who instilled the drug Glaubrinza, 1 drop 2 times a day. The comparison group consisted of 30 patients (60 eyes), whom the drug Simbrinza was instilled according to the same scheme as the drug Glaubrinza.All patients underwent a general ophthalmological examination and special research methods, including: computer static perimetry, pachymetry, and optical coherence tomography (OCT). The local and general tolerability of the drug was assessed within 10 days using a standard scale.Results. The effectiveness of the treatment in the main group was assessed as high in 85% and moderately high in 15% and averaged 3.8±0.1 points. The effectiveness of treatment in the comparison group was assessed as moderately high in 20% and high in 80% of patients and averaged 3.8±0.03 points.Conclusions. Glaubrinza is a highly effective drug for treating POAG and is not inferior in all studied parameters to the reference drug and is also economically accessible to all segments of the population.
6 November 2025 in Advanced Ophthalmology
Relevance. Keratoconus is one of the most significant progressive corneal diseases, leading to visual impairment in young individuals. Timely diagnosis and the selection of an individualized treatment strategy make it possible to slow disease progression, preserve vision, and postpone the need for corneal transplantation. Purpose of the study. To develop an algorithm for a personalized approach to the treatment of keratoconus depending on the stage of the disease. Materials and methods. An analysis of contemporary publications (PubMed, Scopus, 2015–2025), clinical guidelines (ESCRS, AAO), as well as the experience of leading centers (ELZA Institute, Europe, Turkey) was conducted. Results and Conclusion. A stepwise algorithm for the treatment of keratoconus has been developed. The analysis identified the main barriers to implementing personalized methods in Uzbekistan, including the lack of modern diagnostic equipment and the absence of a national keratoconus registry. A personalized stage-based approach to keratoconus management allows optimization of treatment strategies and postponement of corneal transplantation.